Evaluation of Serum Adiponectin Level in Egyptian Breast Cancer Patients before and after Treatment
/ 0
- Details
- Category: Vol. 78, June 2010
- Hits: 645
Evaluation of Serum Adiponectin Level in Egyptian Breast Cancer Patients before and after Treatment, AMR S. MOHAMAD, AZZA N. TAHER, AZZA A. MOHAMAD and MOUSTAFA S. ELNASR
Abstract
Serum adiponectin level was evaluated in thirty five primary breast cancer patients, before and after treatment and ten healthy females with matched age and socioeconomic status, to assess if there is a relation between it and breast cancer, and to find out if it could have a prognostic value. Serum adiponectin level was significantly lower in all and postmenopausal breast cancer patients, before taking any type of treatment, and non-significantly lower in locally advanced breast cancer patients after treatment by 4 cycles of neoadjuvant chemotherapy than healthy controls. Non-significant elevations was shown after treatment by surgery, and also after completing treatment by surgery followed by taking 2 cycles of adjuvant chemotherapy followed by treatment by radiotherapy in case of premenopausal locally advanced breast cancer patients. Triglycerides showed significantly high level in all groups of patients. There was statistical negative correlation between serum adiponectin level and body mass index (BMI) in post-menopausal healthy controls, and between serum adiponectin level and BMI, triglycerides in all and postmenopausal breast cancer patients before taking any type of treatment. In con-clusion, this study shows that low serum adiponectin level is likely to be associated with increased breast cancer risk, particularly among postmenopausal women. The association between obesity and breast cancer risk might be partly ex-plained by adiponectin.